ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0268

Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
Abstract Number: 0269

Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group
Abstract Number: 0270

Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria
Abstract Number: 0271

Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
Abstract Number: 0272

Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice
Abstract Number: 0273

Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Abstract Number: 0274

Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Abstract Number: 0275

A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Abstract Number: 0276

Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis
Abstract Number: 0277

A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Abstract Number: 0278

Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Abstract Number: 0279

Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Abstract Number: 0280

Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
Abstract Number: 0281

Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Abstract Number: 0282

Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].